175 related articles for article (PubMed ID: 33842876)
1. Aging-associated skeletal muscle defects in HER2/Neu transgenic mammary tumor model.
Wang R; Kumar B; Bhat-Nakshatri P; Prasad MS; Jacobsen MH; Ovalle G; Maguire C; Sandusky G; Trivedi T; Mohammad KS; Guise T; Penthala NR; Crooks PA; Liu J; Zimmers T; Nakshatri H
JCSM Rapid Commun; 2021; 4(1):24-39. PubMed ID: 33842876
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer.
Wang R; Bhat-Nakshatri P; Padua MB; Prasad MS; Anjanappa M; Jacobson M; Finnearty C; Sefcsik V; McElyea K; Redmond R; Sandusky G; Penthala N; Crooks PA; Liu J; Zimmers T; Nakshatri H
Mol Cancer Ther; 2017 Dec; 16(12):2747-2758. PubMed ID: 28978719
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations.
Wang R; Kumar B; Doud EH; Mosley AL; Alexander MS; Kunkel LM; Nakshatri H
Mol Ther Nucleic Acids; 2022 Jun; 28():231-248. PubMed ID: 35402076
[TBL] [Abstract][Full Text] [Related]
4. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
5. Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle.
Chen D; Goswami CP; Burnett RM; Anjanappa M; Bhat-Nakshatri P; Muller W; Nakshatri H
Cancer Res; 2014 Aug; 74(16):4270-81. PubMed ID: 24980554
[TBL] [Abstract][Full Text] [Related]
6. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
7. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.
Little JL; Serzhanova V; Izumchenko E; Egleston BL; Parise E; Klein-Szanto AJ; Loudon G; Shubina M; Seo S; Kurokawa M; Ochs MF; Golemis EA
Oncogene; 2014 Jan; 33(4):411-20. PubMed ID: 23318423
[TBL] [Abstract][Full Text] [Related]
8. Systemic Actions of Breast Cancer Facilitate Functional Limitations.
Wang R; Nakshatri H
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31941005
[TBL] [Abstract][Full Text] [Related]
9. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
[TBL] [Abstract][Full Text] [Related]
10. Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice.
Santos JMO; Moreira-Pais A; Neto T; Peixoto da Silva S; Oliveira PA; Ferreira R; Mendes J; Bastos MMSM; Lopes C; Casaca F; Silva S; Sweeney C; Medeiros R; Gil da Costa RM
Drug Dev Res; 2019 Sep; 80(6):824-830. PubMed ID: 31301186
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: preclinical evaluation of interleukin-15 targeting fatigue.
Bohlen J; McLaughlin SL; Hazard-Jenkins H; Infante AM; Montgomery C; Davis M; Pistilli EE
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):701-714. PubMed ID: 29582584
[TBL] [Abstract][Full Text] [Related]
12. Exercise reduces intramuscular stress and counteracts muscle weakness in mice with breast cancer.
Mader T; Chaillou T; Alves ES; Jude B; Cheng AJ; Kenne E; Mijwel S; Kurzejamska E; Vincent CT; Rundqvist H; Lanner JT
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1151-1163. PubMed ID: 35170227
[TBL] [Abstract][Full Text] [Related]
13. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K
Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982
[TBL] [Abstract][Full Text] [Related]
14. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
Fry EA; Taneja P; Inoue K
Int J Cancer; 2017 Feb; 140(3):495-503. PubMed ID: 27553713
[TBL] [Abstract][Full Text] [Related]
16. Mutant RAS-driven secretome causes skeletal muscle defects in breast cancer.
Wang R; Khatpe AS; Kumar B; Mang HE; Batic K; Adebayo AK; Nakshatri H
Cancer Res Commun; 2024 Apr; 4(5):1282-95. PubMed ID: 38651826
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
18. Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice.
Wong AW; Dunlap SM; Holcomb VB; Nunez NP
Alcohol Clin Exp Res; 2012 Apr; 36(4):577-87. PubMed ID: 21981381
[TBL] [Abstract][Full Text] [Related]
19. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
[TBL] [Abstract][Full Text] [Related]
20. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
